SciSparc subsidiary NeuroThera advances MDMA-PEA PTSD patent filing with Clearmind
SPRC•SPRC•SPRC•SPRC•SciSparc subsidiary NeuroThera advanced its collaboration with Clearmind via publication of a U.S. patent application for MDMA plus N-acylethanolamines.
The application targets PTSD treatment and also covers anxiety and eating disorders, potentially affecting MDMA dosing, side effects, potency and therapeutic window.
The collaboration has generated 13 published patent applications globally, expanding the joint intellectual property portfolio around PEA-enabled psychedelic programs.
The FDA finalized psychedelic clinical development guidance on July 14, 2026; the guidance explicitly includes MDMA, shaping the regulatory context for the program.
